Indian Journal of Pharmacology Home 

RESEARCH ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2014  |  Volume : 46  |  Issue : 3  |  Page : 328--333

Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats

Hitesh M Soni1, Amit M Vekaria2, Akshyaya C Rath3, Sateesh Belemkar5, Mukul R Jain3 
1 Department of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, Ahmedabad, Gujarat, India; Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
2 Department of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, Ahmedabad, Gujarat; Department of Pharmacology, School of Pharmacy and Technology Management (Shirpur Campus), Narsee Monjee Institute of Management Studies University, Mumbai, Maharashtra, India
3 Departments of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, Ahmedabad, Gujarat, India

Correspondence Address:
Hitesh M Soni
Department of Pharmacology, Zyd us Research Centre, Sarkhej-Bavla, Moraiya, Ahmedabad, Gujarat, India; Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee, USA

Objectives: The cytokine erythropoietin is the primary stimulator of erythropoiesis and recombinant human erythropoietin (rHuEPO), which is widely used in the treatment of anemia associated with advanced chronic kidney disease (CKD). Adverse cardiovascular outcomes have been observed during clinical trials of anemia correction with rHuEPO in CKD patients. We investigated the effects of short-term, high-dose treatment with rHuEPO on platelet reactivity and effects of aspirin on platelet reactivity in healthy rats. Materials and Methods: Animals received three daily dose of rHuEPO (25 μg/kg s.c.). Platelets were isolated after 48 h of last dose of rHuEPO to study the arachidonic acid-induced platelet aggregation. Aspirin (75 mg/kg p.o.) was given to animals just before 1 h of isolation of platelets. Results: In rats, treatment with rHuEPO increased platelet reactivity and platelet count. The increased platelet reactivity was paralleled by decreased time-to-occlusion (TTO) in arterial thrombosis model, and decreased bleeding time after tail transection in rats. Treatment with rHuEPO followed by single dose of aspirin showed significant reduction in TTO and bleeding time as compared with aspirin-treated group. Conclusions: These findings suggest that rHuEPO increases platelet reactivity and aspirin normalizes the hyper-reactive platelet and may reduce the cardiovascular events associated with rHuEPO in CKD patients.


How to cite this article:
Soni HM, Vekaria AM, Rath AC, Belemkar S, Jain MR. Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats.Indian J Pharmacol 2014;46:328-333


How to cite this URL:
Soni HM, Vekaria AM, Rath AC, Belemkar S, Jain MR. Use of Aspirin in normalization of recombinant human erythropoietin-mediated hyper-reactivity of platelets in rats. Indian J Pharmacol [serial online] 2014 [cited 2021 Dec 9 ];46:328-333
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2014;volume=46;issue=3;spage=328;epage=333;aulast=Soni;type=0